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Abstract This multicenter, double-blind study evaluated
the effects of three doses of adalimumab in Japanese
patients with rheumatoid arthritis (RA). Patients were
randomized to placebo (n = 87) or adalimumab 20 mg
(n = 87), 40 mg (n = 91), or 80 mg (n = 87) every other
week for 24 weeks. The primary efﬁcacy endpoint was the
American College of Rheumatology criteria for 20%
improvement (ACR20) at Week 24. At Week 24, all ada-
limumab treatment groups achieved statistically
signiﬁcantly better ACR20 response rates (20 mg: 28.7%,
P\0.05; 40 mg: 44.0%, P\0.001; and 80 mg: 50.6%,
P\0.001) versus placebo (13.8%), as well as statistically
signiﬁcantly greater ACR50 and ACR70 responses for the
two higher adalimumab doses versus placebo. Rates of
adverse events were comparable between the adalimumab
groups and the placebo group, except for injection-site
reactions, which occurred in more adalimumab-treated
patients. Adalimumab 20, 40, and 80 mg were safe and
effective in Japanese patients; however, the greatest
responses occurred with the 40 and 80 mg doses. These
results and comparable ACR20 responses in Western
patients support adalimumab 40 mg every other week as
the appropriate dosage to treat RA in Japanese patients.
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Introduction
Rheumatoid arthritis (RA) is the most common inﬂam-
matory arthritis, estimated to affect between 0.5 and 1.0%
of the adult population worldwide [1]. Geographic differ-
ences in the incidence of RA in a particular country may be
associated with genetic, environmental, or cultural factors
[1]. Moreover, differences in ethnicity, medical status, and
socioeconomic status may affect response to RA treatment
[2].
In Japan, it is estimated that more than 700,000 patients
within a population of 120 million have RA [3]. Of those
afﬂicted, 70% are women and 10% are bedridden; the
morbidity rate is estimated to be 0.5% [3, 4]. In Japanese
patients, RA is an independent risk factor for mortality [5].
In the past decade, the treatment of RA has dramatically
changed with the introduction of biologics that target
inﬂammatory cytokines, such as tumor necrosis factor
(TNF) [6–8]. Recently, the TNF antagonists inﬂiximab (in
combination with methotrexate [MTX]) and etanercept
have demonstrated efﬁcacy in Japanese patients with RA
[2, 9–11]. Adalimumab is the ﬁrst fully human monoclonal
antibody that binds with high speciﬁcity to TNF [12].
Adalimumab has been well established in the treatment of
patients with RA in multiple clinical trials conducted in
North America [13] and in Europe, [14] both with and
without concomitant MTX.
The objective of this study (CHANGE: Clinical inves-
tigation in Highly disease-affected rheumatoid Arthritis
patients in Japan with Adalimumab applying staNdard and
General Evaluation) was to evaluate the safety, efﬁcacy,
and pharmacokinetics of three different doses of subcuta-
neous adalimumab compared with placebo in Japanese
patients with RA. In addition, this study was designed as a
bridging study to compare efﬁcacy and safety results with
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conducted in Western patients with RA [14].
Although adalimumab in Western regions of the world
is primarily used in combination with MTX, this study
evaluated adalimumab monotherapy and compared the
results with the Western study in which adalimumab was
also evaluated as monotherapy. Moreover, the combination
of adalimumab and MTX was not used in this bridging
study because of differences in MTX dosages used in Japan
and Western countries. The maximum approved oral MTX
dosage in Japan is 8 mg/week, which is much lower than
the 15–20 mg/week dosage commonly used in Western
countries [2, 8, 15, 16].
Patients and methods
Male and female patients aged 20 years or older were
recruited from 68 sites in Japan. Eligible patients met the
American College of Rheumatology (ACR) criteria for
active RA, had failed treatment with at least one prior
disease-modifying antirheumatic drug (DMARD), and had
C10 swollen joints and C12 tender joints (excluding distal
interphalangeal joints) at both the screening visit and
baseline visit. Patients also had a C-reactive protein (CRP)
concentration C2 mg/dl.
Patients taking a DMARD, including MTX, must have
discontinued DMARDs at least 28 days prior to study drug
administration and returned for baseline visit within
42 days. Use of a live vaccine within 3 months; treatment
with an investigational biologic, including anti-CD4 anti-
body, within 6 months; or prior treatment with any TNF
antagonist or an alkylating agent was not permitted.
Exclusion criteria included patients with acute inﬂam-
matory joint diseases other than RA, active Listeria or
tuberculosis, lymphoma, or leukemia, or any malignancy
except for successfully treated nonmetastatic basal-cell
carcinoma of the skin. Patients with positive serology for
anti-human immunodeﬁciency virus antibody, hepatitis B
virus surface antigen, or anti-hepatitis C virus antibody,
ongoing or active infection, advanced or poorly controlled
diabetes, or central nervous system demyelinating disor-
ders were also excluded.
Patients with positive chest X-ray or strongly positive
tuberculin skin test (C10 mm diameter of erythema and
double redness/bullae/necrosis) could not be enrolled.
Patients with a positive (C5 mm of induration), but not
strongly positive, tuberculin skin test could be enrolled if
receiving prophylactic isoniazid 300 mg daily at least three
weeks prior to baseline.
A negative pregnancy test and use of reliable contra-
ception were mandatory for women of childbearing
potential. All patients were required to give written
informed consent. This study was conducted in compliance
with the study protocol, the standards of the Pharmaceu-
tical Affairs Law, the Ministerial ordinance concerning
Good Clinical Practice, and all other applicable regulatory
requirements.
Study design
This was a Phase II/III, multicenter, double-blind, placebo-
controlled trial comparing three different doses of ada-
limumab given as monotherapy performed from February
2004 through June 2005.
Patient eligibility was determined at screening and at
baseline, during the period from 28 to 42 days prior to
study drug administration for patients who required a wash-
out period for DMARD therapy, and within 42 days prior
to study drug administration for all other patients. Patients
were randomly assigned in a 1:1:1:1 ratio to four treatment
groups: 20 mg adalimumab every other week (eow), 40 mg
adalimumab eow, 80 mg adalimumab eow, or placebo
eow, administered by subcutaneous injection starting at
Week 0 and continuing until Week 22. Study drug was
administered by a physician or nurse supervised by an
investigator.
Patients who experienced an increase in disease activity
or who had less than 10% reduction in tender joint counts
(TJC) and swollen joint counts (SJC) compared with
baseline after at least eight weeks of treatment stopped
study therapy with adalimumab/placebo and were switched
to an open-label rescue treatment that could include higher
doses of steroids, nonsteroidal antiinﬂammatory drugs, or
conventional DMARDs. Patients completing 24 weeks of
treatment, either double-blind or open-label rescue, had the
option to enter an open-label extension study to receive
40 mg of adalimumab eow.
Efﬁcacy assessment
The primary efﬁcacy endpoint was ACR20 response rate at
Week 24 for the adalimumab 40 and 80 mg groups com-
pared with placebo. The comparison between ACR20
response rates at Week 24 for the adalimumab 20 mg
group and the placebo group was a secondary endpoint.
The ACR components were evaluated at Weeks 0 (pre-
dose), 2, 4, 8, 12, 16, 20, and 24. Additional secondary
efﬁcacy endpoints included ACR20 response rate at Week
12; ACR50 and ACR70 response rates at Weeks 12 and 24;
individual components of the ACR response (including
TJC and SJC) at Weeks 0 (baseline), 12, and 24; and the
Health Assessment Questionnaire Disability Index (HAQ
DI) at Weeks 0 (baseline), 12, and 24. Morning stiffness
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24; and rheumatoid factor (RF) was evaluated at Weeks 0
(predose), 12, and 24. In addition, ACR20 area under the
curve (AUC) over the 24-week study period was deter-
mined. ACR20 AUC was deﬁned as the sum of the
duration that patients achieved an ACR20 response.
Pharmacokinetic analyses
Pharmacokinetic analyses included serum adalimumab
concentrations and serum anti-adalimumab antibody
(AAA) concentrations, which were determined using a
validated enzyme-linked immunosorbent assay (ELISA)
based on a double-antigen technique. The lower limit of
quantitation for adalimumab and AAA were established at
2.5 and 0.5 ng/mL, respectively, in diluted serum. Because
of interference of adalimumab concentrations with the
AAA assay, AAA concentrations were analyzed only if the
adalimumab concentration was less than 2 lg/mL.
Blood samples for serum adalimumab concentrations
were collected at Weeks 0 (immediately prior to dosing), 2,
4, 8, 12, 16, 20, and 24 (or following the last dose) and at
the follow-up visit. Blood samples for AAA concentrations
were collected at Weeks 0 (immediately prior to dosing), 4,
8, 12, 16, 20, and 24 (or following the last dose) and at the
follow-up visit.
Safety assessment
Safety was evaluated on the basis of treatment-emergent
adverse events (AEs). Laboratory tests, including hema-
tology tests, clinical chemistry tests, and urinalysis, were
conducted at screening; at Weeks 0 (predose), 2, 4, 8, 12,
16, 20, and 24 (or last dose); and at the follow-up visit.
Vital signs and physical examinations were also evaluated.
Comparisons were made of changes from Week 0 (pre-
dose) during treatment for all treatment groups.
Statistical analysis
To detect a difference of 25% in ACR20 response rates
between the placebo group and the adalimumab 40 mg
group, assuming an ACR response rate of 20% in the
placebo arm and 45% in the 40 mg eow arm, a sample size
of 74 patients per treatment group was estimated to be
required to provide 80% power for a two-sided test (con-
tinuity corrected) with an alpha of 0.025. Therefore, taking
the exclusion analysis into consideration, a total of 320
subjects (80 subjects per treatment group) needed to be
equally allocated to one of the four treatments: 20 mg
adalimumab, 40 mg of adalimumab, 80 mg adalimumab,
or placebo.
Demographic and baseline characteristics were com-
pared among the four treatment groups using the one-way
analysis of variance test for continuous variables and the v
2
test for categorical variables. All efﬁcacy analyses were
primarily performed on the full analysis set population,
deﬁned as all randomized patients who received at least
one dose of study drug and from whom at least one
assessment of efﬁcacy under double-blind medication was
available. Unless otherwise speciﬁed, statistical signiﬁ-
cance was set at P = 0.05 (two-sided) for all tests. The
effect of study centers was analyzed; however, because
there were not enough patients per treatment per center,
study center was not adjusted in the statistical analyses.
The primary efﬁcacy endpoint, ACR20 response rate at
Week 24, was compared for the placebo group against that
of the 40 and 80 mg eow adalimumab groups, using the
Pearson v
2 test. The Hochberg procedure was applied to
control for multiplicity of testing. If both P values were
less than 0.05, then the individual null hypotheses (no
treatment difference between adalimumab and the placebo)
were rejected. If one P value did not show signiﬁcance at
0.05, then the other hypothesis was tested against and
adjusted at the 0.025 level. If the test was signiﬁcant at the
adjusted 0.025 level, then the null hypothesis was rejected.
The response rate for ACR20 between the adalimumab
20 mg group and placebo at Week 24 was a secondary
endpointandwascomparedusingthePearsonv
2test.Forthe
additional secondary endpoints, ACR20 at Week 12 and
ACR50 and ACR70 at Weeks 12 and 24, number of
responders and response rates were presented in each group.
Improvements in individual components of the ACR
response at Week 0 (predose) and at Weeks 12 and 24 were
presented as summary statistics for each treatment group,
and comparisons between the placebo group and each
adalimumab group were performed using analysis of
covariance, with baseline values as covariates. For ACR20
AUC,summarystatisticsbytreatmentgroupwerepresented.
Patients who discontinued the study prior to Week 24 or
who moved to the rescue arm following at least eight
weeks of treatment were classiﬁed as nonresponders. In
addition, the last observation carried forward post baseline
was conducted for the following analyses: ACR20 response
rate at Week 24; ACR50 and ACR70 at Weeks 12 and 24;
ACR20 at Week 12; individual components of the ACR
response at Weeks 0 (predose), 12, and 24; and ACR20
AUC. The last non-missing visit up to and including the
Week-24 assessment for each patient was summarized as
the endpoint visit.
All patients who received at least one dose of double-
blind study medication were included in the safety analysis.
Summary statistics included frequency tabulations and
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Activities, version 8.0, preferred term and system organ
class for each treatment group.
Results
A total of 482 patients were screened and 352 patients met
the entry criteria and were randomized to the four treatment
groups (placebo, n = 87; adalimumab 20 mg, n = 87;
adalimumab 40 mg, n = 91; adalimumab 80 mg, n = 87).
A total of 34 (9.7%) of 352 patients discontinued treatment
(7, 7, 16, and 4 in the placebo and adalimumab 20, 40,
and 80 mg groups, respectively) (Fig. 1). Three of the
34 discontinuations occurred during the rescue period.
Discontinuations because of AEs occurred in 4 (4.6%), 5
(5.7%),12(13.2%),and3(3.4%)patients,intheplaceboand
adalimumab 20, 40, and 80 mg groups, respectively. Other
reasons for early discontinuation included withdrawal of
consent, protocol violations, and administrative reasons. A
total of 107 patients received rescue medication after C8
weeks of double-blind study treatment (45, 26, 17, and 19 in
the placebo and adalimumab 20, 40, and 80 mg groups,
respectively). The three discontinuations that occurred
during the rescue period occurred in one patient each from
the original placebo, adalimumab 40 mg, and adalimumab
80 mg groups. A total of 312 (98.1%) of 318 patients who
completed the study entered the extension study and 309
patients continued treatment with adalimumab.
Baseline demographics and disease-state characteristics
are included in Table 1. For the overall study group, the
mean age was 54.9 years, 79.5% of patients were female,
the mean weight was 53.7 kg, the mean duration of RA
was 9.5 years, and the mean TJC and SJC were 24.4 and
19.6, respectively. Baseline demographics were similar
between groups. Baseline disease characteristics were
consistent with what is generally observed in patients with
RA with moderate to severe disease and were comparable
between treatment groups with the following exceptions:
the mean of the patient’s global assessment of disease
activity for the placebo group (64.6 mm) was lower than
those for the adalimumab groups (20 mg: 73.1 mm;
40 mg: 71.2 mm; 80 mg: 75.7 mm; P = 0.003); the mean
of HAQ DI for the placebo group (1.39) was lower than
those for the adalimumab groups (20 mg: 1.57; 40 mg:
1.64; 80 mg: 1.77; P = 0.010); and the mean CRP for the
20 mg group (4.97 mg/dl) was lower than those for other
groups (placebo: 5.86 mg/dl; 40 mg: 6.48 mg/dl; 80 mg:
6.56 mg/dl; P = 0.020).
All patients had previously used one or more DMARDs,
and 91.5% (322/352) of the randomized patients had pre-
viously used two or more DMARDs. The most common
previous DMARDs were MTX (87.2%), salazosulfapyri-
dine (sulfasalazine: 73.9%), and bucillamine (67.6%). More
than half (60.5%) of the patients used previous RA treat-
ments other than DMARDs. The most common previous
RA treatments other than DMARDs were prednisolone
(29.3%), diclofenac (10.8%), and triamcinolone (8.5%).
Received treatment
n =352
Dropped out during the
screening period
n =130
Placebo eow
n =87
Adalimumab 20 mg eow Adalimumab 40 mg eow Adalimumab 80 mg eow
n =87 n =91 n =87
Discontinued
n =7
Discontinued
n =7
Discontinued
n =16
Discontinued
n =4
Completed
study
n =36
Completed
study
n =54
Completed
study
n =59
Completed
study
n =65
Rescue
treatment
n =44
Rescue
treatment
n =26
Rescue
treatment
n =16
Rescue
treatment
n =18
Not into the
extension study
Not into the
extension study
Not into the
extension study
Not into the
extension study
n = 2 n =1 n =3 n =0
Into the extension
study
Into the extension
study
Into the extension
study
Into the extension
study
n =78 n =79 n =72 n =83
Acquired consent
n =482
Fig. 1 Disposition of patients
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At Week 24, adalimumab demonstrated dose-dependent
increases in ACR20 response rates and all adalimumab
treatment groups achieved statistically signiﬁcantly higher
ACR20 responses (28.7% in the 20 mg group, P\0.05;
44.0% in the 40 mg group, P\0.001; and 50.6% in the
80 mg group, P\0.001) compared with the placebo group
(13.8%) (Table 2).
ACR20, ACR50, and ACR70 response rates
Similarly, ACR20 response rates at Week 12 were statis-
tically signiﬁcantly greater in all adalimumab treatment
groups compared with placebo (Table 2). ACR50 and
ACR70 responses were statistically signiﬁcantly greater in
all adalimumab treatment groups compared with placebo at
Weeks 12 and 24, except for the ACR50 response for the
20 mg group at Week 24 and the ACR70 response for the
20 mg group at Week 12 (Table 2). Overall, the increases
in adalimumab ACR20, ACR50, and ACR70 response
rates were time dependent (Fig. 2). All adalimumab treat-
ment groups showed ACR20 response rates exceeding 30%
at Week 2. For the 40 and 80 mg groups, ACR20 response
rates were maintained during the study. However, for the
20 mg group, ACR20 responses fell gradually from Week
16 until the end of the study. In general, ACR50 and
ACR70 responses had the tendency to increase with time in
each treatment group (Fig. 2).
ACR core components
For both the 40 and 80 mg groups, all individual ACR
components showed statistically signiﬁcant improvement
compared with the placebo group (P\0.05) at Week 24,
with the exception of patient’s assessment of pain for the
80 mg group and HAQ DI for the 40 and 80 mg groups
(Table 3). For the 20 mg group, there was only signiﬁcant
Table 1 Baseline demographics and disease characteristics
Placebo
(n = 87)
20 mg
(n = 87)
40 mg
(n = 91)
80 mg
(n = 87)
All doses
(n = 265)
Mean age (year) 53.4 ± 12.8 54.8 ± 12.5 56.9 ± 10.3 54.3 ± 10.9 55.3 ± 11.3
Female, n (%) 67 (77.0) 69 (79.3) 72 (79.1) 72 (82.8) 213 (80.4)
Body weight (kg) 53.7 ± 10.1 55.2 ± 8.6 53.6 ± 9.6 52.4 ± 10.5 53.7 ± 9.7
Duration of RA (year) 8.4 ± 8.2 10.0 ± 7.7 9.9 ± 7.9 9.5 ± 8.3 9.8 ± 8.0
TJC 23.7 ± 8.8 24.6 ± 11.1 24.4 ± 10.7 24.9 ± 10.7 24.6 ± 10.8
SJC 19.3 ± 7.0 19.2 ± 8.4 19.1 ± 7.3 20.8 ± 7.9 19.7 ± 7.9
Physician’s global assessment of disease activity VAS (mm) 74.1 ± 15.6 72.3 ± 15.6 76.2 ± 14.7 76.4 ± 16.4 75.0 ± 15.6
Subject’s global assessment of disease activity VAS (mm) 64.6 ± 22.9 73.1 ± 19.2 71.2 ± 19.7 75.7 ± 19.3 73.3 ± 19.4
Subject’s assessment of pain VAS (mm) 62.7 ± 22.8 69.0 ± 21.3 68.1 ± 21.0 70.4 ± 21.4 69.2 ± 21.2
HAQ DI 1.39 ± 0.75 1.57 ± 0.78 1.64 ± 0.70 1.77 ± 0.74 1.66 ± 0.74
CRP (mg/dl) 5.86 ± 3.30 4.97 ± 3.42 6.48 ± 4.45 6.56 ± 3.87 6.01 ± 4.00
Duration of morning stiffness (min) 195.5 ± 329.4 216.7 ± 367.6 193.3 ± 317.6 202.3 ± 330.6 203.9 ± 337.7
Any morning stiffness, n (%) 75 (86.2) 70 (81.4) 70 (76.9) 76 (88.4) 216 (82.1)
Positive rheumatoid factor, n (%) 75 (86.2) 79 (90.8) 81 (89.0) 81 (93.1) 241 (90.9)
Data are presented as mean ± SD unless otherwise noted
VAS visual analog scale
Table 2 ACR20, ACR50, and ACR70 response rates at Week
12 and Week 24
Placebo
n = 87
n (%)
Adalimumab
20 mg
n = 87
n (%)
40 mg
n = 91
n (%)
80 mg
n = 87
n (%)
ACR20
Week 12 11 (12.6) 39 (44.8)
a 39 (42.9)
a 47 (54.0)
a
Week 24 12 (13.8) 25 (28.7)
a 40 (44.0)
b 44 (50.6)
b
ACR50
Week 12 3 (3.4) 16 (18.4)
a 19 (20.9)
a 23 (26.4)
a
Week 24 5 (5.7) 14 (16.1) 22 (24.2)
a 28 (32.2)
a
ACR70
Week 12 1 (1.1) 6 (6.9) 15 (16.5)
a 10 (11.5)
a
Week 24 1 (1.1) 9 (10.3)
a 11 (12.1)
a 13 (14.9)
a
ACR20 at Week 24 for adalimumab 40 and 80 mg groups compared
with placebo was the primary efﬁcacy endpoint
a P\0.05 versus placebo based on v
2 test
b P\0.0001 versus placebo based on v
2 test
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123improvement in SJC compared with the placebo group at
Week 24. After adjusting for lower baseline CRP levels in
the 20 mg group, results of subgroup analyses found that
CRP had a statistically signiﬁcant relationship to the
ACR20 response rate (odds ratio: 0.9); however, its effect
on the primary efﬁcacy endpoint evaluation was small.
ACR20 response rates in all adalimumab groups with the
adjustments were still statistically signiﬁcantly greater
compared with placebo response rates, as achieved without
the adjustments.
Morning stiffness
At Week 24, greater percentages of patients in each
adalimumab treatment group reported complete resolu-
tion of baseline morning stiffness (17.1% in the 20 mg
group, 22.9% in the 40 mg group, and 25.0% in the
80 mg group) compared with the placebo group (6.7%).
At Week 24, the mean observed duration of morning
stiffness compared with baseline decreased by 55.8, 87.6,
and 137.0 min in the 20, 40, and 80 mg adalimumab
groups, respectively, versus 5.9 min in the placebo
group.
RF status
Of the RF-positive patients at baseline, 3.4, 6.0, 9.8, and
6.7% of patients in the placebo and adalimumab 20, 40,
and 80 mg groups, respectively, shifted to RF-negative at
Week 24, with no signiﬁcant differences between groups.
Of the RF-negative patients at baseline, two patients (one
in the placebo group and one in the adalimumab 40 mg
group) shifted to RF-positive at Week 24.
Pharmacokinetic analysis
Serum trough concentrations of adalimumab reached a
steady state approximately by Week 8 and remained
relatively constant through Week 24 (Fig. 3a). Serum
adalimumab concentrations were lower in the lower
dose groups (20 and 40 mg) compared with the 80 mg
group.
The percentages of patients who had at least one AAA-
positive serum sample from the start of study drug treat-
ment until 30 days after the last dose were 40.2, 44.0, and
26.4% in the 20, 40, and 80 mg adalimumab groups,
respectively. The distribution of serum AAA-positive
concentrations is shown in Fig. 3b. The majority of
patients who were positive for AAA had relatively low
titers. Mean serum adalimumab concentrations over time
stratiﬁed by AAA status are depicted in Fig. 3c. Concen-
tration-versus-time curves normalized once AAA status
was considered.
For ACR20 response rate at Week 24, the AAA-positive
patients (14.3, 27.5, and 34.8%) in the adalimumab 20, 40,
and 80 mg groups showed lower response rates than AAA-
negative patients (38.5, 56.9, and 56.3%), respectively.
ACR50 response at Week 24 showed a similar tendency
(AAA-positive [5.0–13.0%] and AAA-negative [19.2–
39.2%]).
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All patients who received at least one injection of study
drug and at least one postbaseline safety evaluation
(n = 352) were included in the safety analysis. Overall,
81.6, 92.0, 98.9, and 93.1% of patients in the placebo and
the adalimumab 20, 40, and 80 mg groups, respectively,
reported at least one treatment-emergent AE during the
double-blind study period (Table 4). The number of AEs
that occurred in the 40 and 80 mg groups were statistically
signiﬁcantly greater compared with the placebo group
(P\0.05 for both groups) (Table 4). The majority of AEs
were mild or moderate in intensity. The most common
treatment-emergent AEs across all treatment groups were
nasopharyngitis, injection site erythema, anti-dsDNA
antibody–positive reaction, and anti–nuclear antibody–
positive reaction. Injection-site reaction was reported by a
statistically signiﬁcantly greater percentage of patients in
each of the adalimumab treatment groups compared with
placebo (Table 4). However, most of these reactions,
although reported frequently, were generally mild or
moderate in nature and rarely led to discontinuation of
treatment. Also, injection-site reactions tended to decrease
over time. Three patients in the adalimumab 40 mg group
discontinued the study because of injection-site reactions.
Severe AEs were reported at similar rates in the ada-
limumab groups and the placebo group (Table 4).
Infectious AEs were also reported at similar rates in the
adalimumab groups and the placebo group. A total of 44
infectious AEs were reported by 36.8% (32/87) of placebo-
treated patients and 161 infectious AEs were reported by
40.8% (108/265) of the adalimumab-treated patients. The
Table 3 Summary of
individual ACR components:
changes from baseline to Week
12 and Week 24
Data based on the full analysis
set with last observation carried
forward
a P\0.05 compared with
placebo based on analysis of
covariance
ACR components visit Placebo
n = 87
Mean ± SD
Adalimumab
20 mg
n = 87
Mean ± SD
40 mg
n = 91
Mean ± SD
80 mg
n = 87
Mean ± SD
TJC
Baseline (value) 23.7 ± 8.8 24.6 ± 11.1 24.4 ± 10.7 24.9 ± 10.7
Study week 12 -0.6 ± 10.6 -8.3 ± 10.2
a -11.2 ± 12.2
a -10.1 ± 11.1
a
Study week 24 -0.5 ± 10.9 -6.6 ± 11.4 -10.7 ± 12.3
a -10.0 ± 13.3
a
SJC
Baseline (value) 19.3 ± 7.0 19.2 ± 8.4 19.1 ± 7.3 20.8 ± 7.9
Study week 12 -1.6 ± 7.2 -6.8 ± 7.7
a -8.1 ± 9.3
a -8.7 ± 8.6
a
Study week 24 -1.8 ± 7.4 -5.9 ± 7.6
a -8.2 ± 8.8
a -8.7 ± 9.4
a
Physician’s global assessment of disease activity (VAS)
Baseline (value) 74.1 ± 15.6 72.3 ± 15.6 76.2 ± 14.7 76.4 ± 16.4
Study week 12 -7.1 ± 19.7 -23.0 ± 24.9
a -31.3 ± 26.6
a -31.9 ± 29.2
a
Study week 24 -8.0 ± 21.8 -20.1 ± 27.8 -30.3 ± 24.8
a -31.0 ± 31.6
a
Patient’s global assessment of disease activity (VAS)
Baseline (value) 64.6 ± 22.9 73.1 ± 19.2 71.2 ± 19.7 75.7 ± 19.3
Study week 12 2.1 ± 21.8 -19.9 ± 26.1
a -19.1 ± 29.0
a -25.9 ± 28.9
a
Study week 24 2.6 ± 23.5 -16.6 ± 27.0 -19.9 ± 31.0
a -25.8 ± 31.6
a
Patient’s assessment of pain (VAS)
Baseline (value) 62.7 ± 22.8 69.0 ± 21.3 68.1 ± 21.0 70.4 ± 21.4
Study week 12 2.3 ± 23.5 -17.3 ± 27.6 -17.2 ± 28.2
a -20.5 ± 29.4
a
Study week 24 3.5 ± 25.4 -12.8 ± 26.0 -17.4 ± 27.9
a -20.3 ± 33.3
HAQ DI score
Baseline (value) 1.4 ± 0.7 1.6 ± 0.8 1.6 ± 0.7 1.8 ± 0.7
Study week 12 0.1 ± 0.6 -0.2 ± 0.5
a -0.3 ± 0.6 -0.4 ± 0.5
a
Study week 24 0.1 ± 0.6 -0.2 ± 0.5 -0.2 ± 0.6 -0.4 ± 0.6
CRP (mg/dl)
Baseline (value) 5.9 ± 3.3 5.0 ± 3.4 6.5 ± 4.4 6.6 ± 3.9
Study week 12 0.2 ± 2.9 -0.6 ± 3.1 -1.6 ± 4.4 -2.3 ± 3.9
a
Study week 24 0.1 ± 3.2 -0.5 ± 3.2 -1.6 ± 4.1
a -2.3 ± 4.0
a
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123most common infectious AE, nasopharyngitis, was repor-
ted by 15.8% of the patients in all of the adalimumab
groups and by 18.4% of placebo-treated patients. The next
most common infectious AE, upper respiratory tract
infection, was reported by 4.5% of adalimumab-treated
patients and by 2.3% of placebo-treated patients. In gen-
eral, the majority of infectious AEs were mild or moderate
in intensity; only ﬁve AEs were considered to be severe by
the investigator (acute bronchitis and two events of pneu-
monia in the 20 mg group and infectious bursitis and
infectious dacryocystitis in the 40 mg group).
Rates of serious AEs were comparable between the
adalimumab groups and the placebo group. Three serious
AEs resulted in death in two patients—one patient in the
adalimumab 40 mg group died from interstitial lung dis-
ease and from lung infection, which was considered
possibly related to treatment, and one patient in the ada-
limumab 80 mg group died from cerebral hemorrhage,
which was considered unrelated to treatment. There were
no reports of malignancies or tuberculosis in the ada-
limumab treatment groups. Malignancies were reported in
two patients in the placebo group during the double-blind
period. There were no clinically relevant differences
between treatment groups in physical examination results,
vital signs, or laboratory measurements. There were some
minor differences in safety proﬁle for AAA-positive
patients and AAA-negative patients, but the differences
were not clinically important. The most notable difference
was the rate of injection-site reactions.
Discussion
In this study of Japanese patients with moderate to severe
RA, three adalimumab dosages (20, 40, and 80 mg eow)
encompassed the range of effective and well-tolerated
dosages shown in previous clinical studies of adalimumab
in North America, Australia, and Europe. [13, 14, 17–19]
For the primary efﬁcacy endpoint—ACR20 response rates
at Week 24—the adalimumab 20, 40, and 80 mg groups
showed dose-dependent improvement and were statistically
signiﬁcantly greater than that seen in placebo-treated
patients. In each adalimumab dosage group, the percentage
of patients achieving an ACR 20 response increased from
Week 1 through Week 12 and continued at that level
through Week 24.
The results of this bridging study in Japanese patients
were intended to be compared with data from a similar
study in Western patients with RA conducted in Europe,
Australia, and Canada [14]. Similar study designs allow for
comparisons between the two study populations. Both
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Fig. 3 a Mean (SD) serum adalimumab concentrations over time.
b Distribution (%) of samples with positive serum anti-adalimumab
antibody (AAA) concentrations. c Mean (SD) predose serum ada-
limumab concentrations (lg/mL) over time in Japanese patients with
rheumatoid arthritis who completed the 24-week study with every-
other-weekly adalimumab treatment stratiﬁed by AAA status
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123studies were multicenter, double-blind, placebo-controlled,
randomized trials. This study in Japanese patients is a
Phase II/III study, which included 352 Japanese patients,
and the Western study was a Phase III study, which
included 544 patients (98.2% white). Both studies included
patients with RA who had an inadequate response to one or
more DMARDs and TJC C 12, SJC C 10, and CRP C 2
mg/dl. This Japanese study evaluated adalimumab 20, 40,
and 80 mg eow; whereas the Western study evaluated
adalimumab 20 and 40 mg eow and 20 and 40 mg weekly.
The 80 mg eow dosage in Japanese patients can be roughly
compared with the 40 mg weekly dosage in Western
patients, achieving a similar dosage over time.
It was not practical to dose adalimumab weekly in this
study conducted in Japanese patients as in the Western
study, because it is generally not standard procedure for
patients in Japan to self-inject their subcutaneous medica-
tions; therefore, weekly visits to receive their study drug
would be inconvenient. Baseline demographics and disease
characteristics were comparable, except for weight and
height, which were lower in Japanese patients, as expected;
TJC was also lower in Japanese patients, but not SJC.
The primary efﬁcacy endpoints were similar—ACR20
at Week 24 (Japanese) and ACR20 at Week 26 (Western).
The results of both studies found comparable ACR
response rates supporting 40 mg eow as the appropriate
standard dose (Fig. 4). ACR20 response rates were 19.1,
35.8, 46.0, and 53.4% in the placebo group and the ada-
limumab 20, 40, and 40 mg/week groups, respectively, in
Western patients. Similarly, ACR20 responses were 13.8,
28.7, 44.0, and 50.6% in the placebo group and the ada-
limumab 20, 40, and 80 mg eow groups, respectively, in
Japanese patients. Serum trough concentrations of ada-
limumab in both Japanese and Western patients were
almost constant after Week 8. However, mean steady-state
serum concentrations of adalimumab in Japanese patients
were lower compared with Western patients in the 40 mg
group and slightly lower in the 20 mg group. There was a
similar inﬂuence of AAAs on efﬁcacy in both studies, with
lower ACR20 response rates in AAA-positive patients than
in AAA-negative patients, although the positivity for AAA
was higher in our study compared with the Western study
(40.2 [20 mg] to 44% [40 mg] versus approximate 12%)
[14]. The reason for the higher percentage of AAA posi-
tivity among Japanese versus Western patients is unknown.
Many of the positive samples showed low concentrations
of AAA (Fig. 3b), which may explain why the overall ACR
response rates are still very comparable. We could also
theorize that, at some time within the 2-week dosing
interval, adalimumab concentrations were sufﬁciently high
to produce the comparable efﬁcacy results seen in this
study. Because only trough (predose) samples were tested
for adalimumab concentrations, we cannot evaluate the
validity of this theory within the context of this study.
Table 4 Treatment-emergent
adverse events
a P\0.05 compared with
placebo (Fisher exact test)
TB tuberculosis
Placebo
(n = 87)
Adalimumab
20 mg
(n = 87)
40 mg
(n = 91)
80 mg
(n = 87)
AE 71 (81.6) 80 (92.0) 90 (98.9)
a 81 (93.1)
a
Serious AE 8 (9.2) 10 (11.5) 17 (18.7) 8 (9.2)
Severe AE 5 (5.7) 3 (3.4) 4 (4.4) 5 (5.7)
Infectious AE 32 (36.8) 30 (34.5) 41 (45.1) 37 (42.5)
Serious infectious AE 1 (1.1) 4 (4.6) 6 (6.6) 3 (3.4)
Injection site reaction 2 (2.3) 27 (31.0)
a 28 (30.8)
a 29 (33.3)
a
Immunologic reaction 0 (0.0) 4 (4.6) 2 (2.2) 0 (0.0)
Malignancies 2 (2.3) 0 (0.0) 0 (0.0) 0 (0.0)
Opportunistic infection including TB 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE leading to death 0 (0.0) 0 (0.0) 1 (1.1) 1 (1.1)
AE leading to early withdrawal 4 (4.6) 5 (5.7) 12 (13.2) 3 (3.4)
Probable or possibly related AEs 32 (36.8) 64 (73.6)
a 67 (73.6)
a 61 (70.1)
a
ACR20 ACR50
13.8
28.7
44
50.6
19.1
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46
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24.2
32.2
8.2
18.9
22.1
35
1.1
10.3
12.1
14.9
1.8
8.5 8.5
18.4
0
10
20
30
40
50
60
40mg/wk
A
C
R
 
R
e
s
p
o
n
s
e
 
(
%
)
 
ACR70
Japanese RA Study Western RA Study
Placebo Placebo 20 mg 20 mg 40 mg 40 mg 80 mg
Fig. 4 Comparison of ACR response rates in Western patients with
RA (Week 26) and Japanese patients with RA (Week 24)
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123Increased positivity for AAA in this study can be ascribed
to monotherapy of adalimumab, as concomitant usage of
MTX is known to signiﬁcantly decrease the incidence of
anti-human chimeric antibody against inﬂiximab [16]. The
lower incidence of AAA in the 80 mg group (26.4%) in
this study compared with the 20 and 40 mg groups may be
explained by the higher dose of adalimumab potentially
inhibiting AAA production. Moreover, the sample size in
this study is smaller than the overall population of RA
patients (N = 1062) in which a 5% incidence of AAA has
been reported [12]. Further study of the clinical importance
of AAA development is warranted.
The safety proﬁles of adalimumab in the two studies
were similar. Minor differences in safety were reported,
most notably injection-site reaction, which was reported at
greater percentages in Japanese patients in all adalimumab
groups (67/265; 25.3%) compared with all adalimumab
dose groups in Western patients (46/434; 10.6%). Almost
all injection-site reactions were considered mild in inten-
sity and were easily manageable with conservative medical
treatment.
Conclusions
Adalimumab 20, 40, and 80 mg eow led to signiﬁcant
improvement in signs and symptoms of RA in Japanese
patients with moderate to severe RA. The greatest treat-
ment responses occurred with the 40 and 80 mg
adalimumab doses. Repeated doses of adalimumab 20, 40,
and 80 mg were generally well-tolerated in Japanese
patients. At the suggested adalimumab dosage in foreign
countries (40 mg eow), similar efﬁcacy, safety, and phar-
macokinetic study results were obtained with Japanese
patients with RA compared with results in Western
patients. Only minor differences in the safety proﬁle
between all three adalimumab groups and the placebo
group were reported in Japanese patients compared with
Western patients, the most notable of which is injection-
site reaction. Therefore, comparable ACR response rates
and safety data support adalimumab 40 mg eow being the
appropriate standard dosage to treat RA in Japanese
patients.
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